Stocks / Stock overview

Moderna, Inc. (MRNA)

$131.62-24.52%Market cap $52.55B
Stock Scorer
Scoring…
Analyst consensus
Hold$89.33
  • Analysts18
  • Implied upside-32.1%
  • Target range$25.00 to $170.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Next earnings
November 5, 2026before the open
  • EPS expected-$1.35
  • A year ago-$0.51
  • Revenue expected$872.9M -14%
  • Estimate range-$3.32 to -$0.80
Consensus of 14 analysts for the quarter ending September 30, 2026. Beat the estimate in all four of the last four quarters. Estimates are what Wall Street expects, not our forecast.

SEC filings

FormFiledDescription
SCHEDULE 13GAugust 12, 2026View on EDGAR
4August 7, 2026PRIMARY DOCUMENT
SCHEDULE 13G/AAugust 6, 2026View on EDGAR
144August 5, 2026View on EDGAR
10-QJuly 31, 202610-Q
8-KJuly 31, 20268-K
SCHEDULE 13G/AJuly 24, 2026View on EDGAR
4July 16, 2026PRIMARY DOCUMENT
All SEC filings

Moderna news

Four Korean stocks hit their 30% daily limit on Moderna's cancer-vaccine trial win. Three actually work in mRNA, and the fourth makes semiconductor equipment.
News

Four Korean stocks hit their 30% daily limit on Moderna's cancer-vaccine trial win. Three actually work in mRNA, and the fourth makes semiconductor equipment.

Somagen, Naibec, Genexine and Samyang Biopharm all hit Korea's 30% daily limit on Moderna's cancer-vaccine trial win, and each has a disclosed mRNA business behind it, except one. Entutech hit the same limit riding a five-year-old rumor. It makes semiconductor equipment.

Aug 20, 2026
Moderna (MRNA) options bought for a penny Tuesday were worth $96 by Wednesday. That's a one-day gain of 965,200%.
News

Moderna (MRNA) options bought for a penny Tuesday were worth $96 by Wednesday. That's a one-day gain of 965,200%.

MRNA call options bought for a penny on Tuesday were worth $96 a share by Wednesday, a 965,200% gain in one day, after Moderna's Merck-partnered melanoma vaccine trial succeeded. A $100 bet on them would have been worth $965,300 if sold at the high.

Aug 20, 2026

Frequently asked questions

When does MRNA report earnings?

Moderna, Inc. (MRNA) is scheduled to report quarterly results on November 5, 2026, before the open. The 14-analyst consensus is -$1.35 per share on revenue of $872.9M for the quarter ending September 30, 2026, against -$0.51 and $1.02B a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters.

What do analysts expect for MRNA?

18 analysts cover Moderna, Inc. (MRNA). The consensus rating is Hold. The average price target is $89.33, in a range of $25.00 to $170.00.

Are insiders buying or selling MRNA?

We have no qualifying Form 4 insider purchases or sales on record for Moderna, Inc. (MRNA). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see MRNA SEC filings?

Recent filings are listed on this page, newest first. The latest is a SCHEDULE 13G filed August 12, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.